Jonathan Aschoff
Stock Analyst at Roth MKM
(0.39)
# 3,018
Out of 4,412 analysts
47
Total ratings
13.33%
Success rate
-32.19%
Average return
Main Sectors:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $4.63 | +763.93% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $3.03 | +824.09% | 3 | Mar 28, 2024 | |
| TFFP TFF Pharmaceuticals | Maintains: Buy | $56 → $44 | $2.96 | +1,386.49% | 1 | Mar 28, 2024 | |
| BPTH Bio-Path Holdings | Maintains: Buy | $12 → $40 | $2.68 | +1,392.54% | 2 | Mar 27, 2024 | |
| PBLA Panbela Therapeutics | Maintains: Buy | $25 | $0.41 | +5,997.56% | 4 | Mar 27, 2024 | |
| FWBI First Wave BioPharma | Maintains: Buy | $40 → $36 | $2.74 | +1,213.87% | 4 | Mar 15, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $25 → $36 | $8.52 | +322.54% | 1 | Mar 7, 2024 | |
| HSDT Helius Medical Technologies | Maintains: Buy | $5 → $24 | $4.72 | +408.47% | 2 | Mar 5, 2024 | |
| TENX Tenax Therapeutics | Reiterates: Buy | $30 | $3.52 | +752.27% | 3 | Feb 20, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $16 → $21 | $1.51 | +1,290.73% | 1 | Dec 19, 2023 | |
| OTRK Ontrak | Initiates: Buy | $4 | $0.29 | +1,265.19% | 1 | Dec 5, 2023 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $25 | $4.52 | +453.10% | 1 | Oct 6, 2023 | |
| CLNN Clene | Reiterates: Buy | $10 | $0.34 | +2,842.04% | 1 | Aug 29, 2023 | |
| IMMX Immix Biopharma | Reiterates: Buy | $14 | $2.13 | +557.28% | 2 | Aug 14, 2023 | |
| BRTX BioRestorative Therapies | Reiterates: Buy | $15 | $1.25 | +1,100.00% | 2 | Aug 14, 2023 | |
| REVB Revelation Biosciences | Maintains: Buy | $150 → $450 | $2.16 | +20,733.33% | 2 | Feb 14, 2023 | |
| OCGN Ocugen | Reinstates: Buy | $8 | $1.28 | +525.00% | 1 | Jun 15, 2022 | |
| CELZ Creative Medical Technology Holdings | Initiates: Buy | $100 | $4.32 | +2,214.81% | 1 | Feb 25, 2022 | |
| BFRI Biofrontera | Initiates: Buy | n/a | $1.59 | - | 1 | Nov 24, 2021 | |
| SEEL Seelos Therapeutics | Upgrades: Buy | $75 → $240 | $0.29 | +82,374.23% | 2 | Sep 27, 2021 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $2,816 → $2,200 | $0.71 | +311,470.60% | 2 | May 28, 2021 | |
| SHLS Shoals Technologies Group | Initiates: Buy | n/a | $8.52 | - | 1 | Mar 11, 2021 | |
| APDN Applied DNA Sciences | Initiates: Buy | n/a | $4.30 | - | 1 | Feb 12, 2021 | |
| INO Inovio Pharmaceuticals | Downgrades: Sell | $96 | $10.57 | +808.23% | 3 | Nov 17, 2020 | |
| ARDS Aridis Pharmaceuticals | Initiates: Buy | n/a | $0.07 | - | 1 | Feb 19, 2020 | |
| AMPE Ampio Pharmaceuticals | Initiates: Buy | n/a | $0.32 | - | 1 | Dec 19, 2019 | |
| INMB INmune Bio | Initiates: Buy | n/a | $11.29 | - | 1 | Dec 19, 2019 |
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $4.63
Upside: +763.93%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $3.03
Upside: +824.09%
TFF Pharmaceuticals
Mar 28, 2024
Maintains: Buy
Price Target: $56 → $44
Current: $2.96
Upside: +1,386.49%
Bio-Path Holdings
Mar 27, 2024
Maintains: Buy
Price Target: $12 → $40
Current: $2.68
Upside: +1,392.54%
Panbela Therapeutics
Mar 27, 2024
Maintains: Buy
Price Target: $25
Current: $0.41
Upside: +5,997.56%
First Wave BioPharma
Mar 15, 2024
Maintains: Buy
Price Target: $40 → $36
Current: $2.74
Upside: +1,213.87%
Mind Medicine (MindMed)
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $8.52
Upside: +322.54%
Helius Medical Technologies
Mar 5, 2024
Maintains: Buy
Price Target: $5 → $24
Current: $4.72
Upside: +408.47%
Tenax Therapeutics
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $3.52
Upside: +752.27%
Cyclacel Pharmaceuticals
Dec 19, 2023
Maintains: Buy
Price Target: $16 → $21
Current: $1.51
Upside: +1,290.73%
Ontrak
Dec 5, 2023
Initiates: Buy
Price Target: $4
Current: $0.29
Upside: +1,265.19%
Zevra Therapeutics
Oct 6, 2023
Reiterates: Buy
Price Target: $25
Current: $4.52
Upside: +453.10%
Clene
Aug 29, 2023
Reiterates: Buy
Price Target: $10
Current: $0.34
Upside: +2,842.04%
Immix Biopharma
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.13
Upside: +557.28%
BioRestorative Therapies
Aug 14, 2023
Reiterates: Buy
Price Target: $15
Current: $1.25
Upside: +1,100.00%
Revelation Biosciences
Feb 14, 2023
Maintains: Buy
Price Target: $150 → $450
Current: $2.16
Upside: +20,733.33%
Ocugen
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.28
Upside: +525.00%
Creative Medical Technology Holdings
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $4.32
Upside: +2,214.81%
Biofrontera
Nov 24, 2021
Initiates: Buy
Price Target: n/a
Current: $1.59
Upside: -
Seelos Therapeutics
Sep 27, 2021
Upgrades: Buy
Price Target: $75 → $240
Current: $0.29
Upside: +82,374.23%
Aptevo Therapeutics
May 28, 2021
Maintains: Buy
Price Target: $2,816 → $2,200
Current: $0.71
Upside: +311,470.60%
Shoals Technologies Group
Mar 11, 2021
Initiates: Buy
Price Target: n/a
Current: $8.52
Upside: -
Applied DNA Sciences
Feb 12, 2021
Initiates: Buy
Price Target: n/a
Current: $4.30
Upside: -
Inovio Pharmaceuticals
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $10.57
Upside: +808.23%
Aridis Pharmaceuticals
Feb 19, 2020
Initiates: Buy
Price Target: n/a
Current: $0.07
Upside: -
Ampio Pharmaceuticals
Dec 19, 2019
Initiates: Buy
Price Target: n/a
Current: $0.32
Upside: -
INmune Bio
Dec 19, 2019
Initiates: Buy
Price Target: n/a
Current: $11.29
Upside: -